JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) — InflaRx NV IFRX (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics that target the complement system, today announced pricing of its underwritten public offering of 9,411,765 common shares at an offer price of $4.25 per common share . The offering is expected to close on April 14, 2023, subject to the satisfaction of customary closing conditions.

The Company has granted the underwriters a 30-day option to purchase up to 1,411,764 additional common shares at the public offering price less the offering discount.

The Company intends to use the net proceeds from the Offering to fund further development of vilobelimab, general research and development expenses and investments in the Company’s commercial infrastructure, working capital and general corporate purposes.

Raymond James & Associates, Inc. is acting as sole book-running manager for the offering and LifeSci Capital, LLC is co-manager.

On July 17, 2020, the U.S. Securities and Exchange Commission (the “SEC”) executed a shelf registration statement relating to the securities sold pursuant to this offering. The offering is being made only by means of a prospectus and a prospectus supplement. The prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, if available, may be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716 by calling (800). 248-8863 or email at Prospectus@raymondjames.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor is it permitted to sell these securities in any state or jurisdiction in…